Literature DB >> 22672968

Expression and characterization of recombinant soluble porcine CD3 ectodomain molecules: mapping the epitope of an anti-porcine CD3 monoclonal antibody 898H2-6-15.

Jaclyn Stromp Peraino1, Christina E Hermanrud, Lauren Springett, Huiping Zhang, Guoying Li, Srimathi Srinivasan, Ashley Gusha, David H Sachs, Christene A Huang, Zhirui Wang.   

Abstract

The porcine CD3 specific monoclonal antibody 898H2-6-15 has been used in allo- and xeno-transplantation studies as a porcine CD3 marker and as an effective T cell depletion reagent when conjugated to the diphtheria toxin mutant, CRM9. A recombinant anti-porcine CD3 immuntoxin was recently developed using single-chain variable fragments (scFv) derived from 898H2-6-15. In this study, using published sequence data, we have expressed the porcine CD3 ectodomain molecules in E. coli through inclusion body isolation and in vitro refolding approach. The expressed and refolded porcine CD3 ectodomain molecules include CD3ε, CD3γ, CD3δ, CD3εγ heterodimer, CD3εδ heterodimer, CD3εγ single-chain fusion protein and CD3εδ single-chain fusion protein. These refolded porcine CD3 ectodomain molecules were purified with a strong anion exchange resin Poros 50HQ. ELISA analysis demonstrated that only the porcine CD3εγ ectodomain single-chain fusion protein can bind to the porcine CD3 specific monoclonal antibody 898H2-6-15. The availability of this porcine CD3εγ ectodomain single-chain fusion protein will allow screening for affinity matured variants of scFv derived from 898H2-6-15 to improve the recombinant anti-porcine CD3 immunotoxin. Porcine CD3εγ ectodomain single-chain fusion protein will also be a very useful reagent to study the soluble phase interaction between porcine CD3εγ and porcine CD3 antibodies such as 898H2-6-15.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22672968      PMCID: PMC3641788          DOI: 10.1016/j.cellimm.2012.05.004

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  17 in total

1.  In vitro production and characterization of partly assembled human CD3 complexes.

Authors:  J Kastrup; L Ø Pedersen; J Dietrich; J P H Lauritsen; C Menné; C Geisler
Journal:  Scand J Immunol       Date:  2002-11       Impact factor: 3.487

2.  Heterodimeric CD3epsilongamma extracellular domain fragments: production, purification and structural analysis.

Authors:  K S Kim; Z Y Sun; G Wagner; E L Reinherz
Journal:  J Mol Biol       Date:  2000-09-29       Impact factor: 5.469

3.  Porcine CD3 epsilon: its characterization, expression and involvement in activation of porcine T lymphocytes.

Authors:  P A Kirkham; H Takamatsu; H Yang; R M Parkhouse
Journal:  Immunology       Date:  1996-04       Impact factor: 7.397

4.  Assembly, specific binding, and crystallization of a human TCR-alphabeta with an antigenic Tax peptide from human T lymphotropic virus type 1 and the class I MHC molecule HLA-A2.

Authors:  D N Garboczi; U Utz; P Ghosh; A Seth; J Kim; E A VanTienhoven; W E Biddison; D C Wiley
Journal:  J Immunol       Date:  1996-12-15       Impact factor: 5.422

5.  Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model.

Authors:  C A Huang; Y Fuchimoto; R Scheier-Dolberg; M C Murphy; D M Neville; D H Sachs
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

6.  Development of a diphtheria toxin based antiporcine CD3 recombinant immunotoxin.

Authors:  Zhirui Wang; Raimon Duran-Struuck; Rebecca Crepeau; Abraham Matar; Isabel Hanekamp; Srimathi Srinivasan; David M Neville; David H Sachs; Christene A Huang
Journal:  Bioconjug Chem       Date:  2011-09-09       Impact factor: 4.774

7.  Yeast surface display for directed evolution of protein expression, affinity, and stability.

Authors:  E T Boder; K D Wittrup
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

8.  Expression and characterization of recombinant soluble human CD3 molecules: presentation of antigenic epitopes defined on the native TCR-CD3 complex.

Authors:  Che-Leung Law; Martha Hayden-Ledbetter; Sonya Buckwalter; Lisa McNeill; Hieu Nguyen; Phil Habecker; Barbara A Thorne; Raj Dua; Jeffrey A Ledbetter
Journal:  Int Immunol       Date:  2002-04       Impact factor: 4.823

9.  Expression and characterization of recombinant soluble monkey CD3 molecules: mapping the FN18 polymorphic epitope.

Authors:  Zhirui Wang; David M Neville
Journal:  Mol Immunol       Date:  2004-03       Impact factor: 4.407

10.  Gene optimization is necessary to express a bivalent anti-human anti-T cell immunotoxin in Pichia pastoris.

Authors:  Jung Hee Woo; Yuan Yi Liu; Askale Mathias; Scott Stavrou; Zhirui Wang; Jerry Thompson; David M Neville
Journal:  Protein Expr Purif       Date:  2002-07       Impact factor: 1.650

View more
  8 in total

1.  Development of a diphtheria toxin-based recombinant porcine IL-2 fusion toxin for depleting porcine CD25+ cells.

Authors:  Jaclyn Stromp Peraino; Marian Schenk; Guoying Li; Huiping Zhang; Evan A Farkash; David H Sachs; Christene A Huang; Raimon Duran-Struuck; Zhirui Wang
Journal:  J Immunol Methods       Date:  2013-09-18       Impact factor: 2.303

2.  Porcine Treg depletion with a novel diphtheria toxin-based anti-human CCR4 immunotoxin.

Authors:  Zhaohui Wang; Nalu Navarro-Alvarez; Jigesh A Shah; Huiping Zhang; Qi Huang; Qian Zheng; Joren C Madsen; David H Sachs; Christene A Huang; Zhirui Wang
Journal:  Vet Immunol Immunopathol       Date:  2016-10-29       Impact factor: 2.046

3.  Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4(+) cells in vivo.

Authors:  Zhaohui Wang; Min Wei; Huiping Zhang; Hongyuan Chen; Sharon Germana; Christene A Huang; Joren C Madsen; David H Sachs; Zhirui Wang
Journal:  Mol Oncol       Date:  2015-04-25       Impact factor: 6.603

4.  Diphtheria toxin-based bivalent human IL-2 fusion toxin with improved efficacy for targeting human CD25(+) cells.

Authors:  Jaclyn Stromp Peraino; Huiping Zhang; Priyani V Rajasekera; Min Wei; Joren C Madsen; David H Sachs; Christene A Huang; Zhirui Wang
Journal:  J Immunol Methods       Date:  2014-01-24       Impact factor: 2.303

5.  Molecular basis of cross-species reactivities of human versus porcine CTLA-4.

Authors:  Jaclyn Stromp Peraino; Huiping Zhang; Guoying Li; Christene A Huang; Zhirui Wang
Journal:  Hum Immunol       Date:  2013-04-18       Impact factor: 2.850

6.  Treg depletion in non-human primates using a novel diphtheria toxin-based anti-human CCR4 immunotoxin.

Authors:  Zhaohui Wang; Shannon G Pratts; Huiping Zhang; Philip J Spencer; Ruichao Yu; Makoto Tonsho; Jigesh A Shah; Tatsu Tanabe; Harrison R Powell; Christene A Huang; Joren C Madsen; David H Sachs; Zhirui Wang
Journal:  Mol Oncol       Date:  2015-11-19       Impact factor: 6.603

7.  Diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19+ tumors.

Authors:  Qian Zheng; Zhaohui Wang; Huiping Zhang; Qi Huang; Joren C Madsen; David H Sachs; Christene A Huang; Zhirui Wang
Journal:  Mol Oncol       Date:  2017-04-04       Impact factor: 6.603

8.  Bispecific human IL2-CCR4 immunotoxin targets human cutaneous T-cell lymphoma.

Authors:  Haoyu Wang; Zhaohui Wang; Huiping Zhang; Zeng Qi; Ariel C Johnson; David Mathes; Elizabeth A Pomfret; Erin Rubin; Christene A Huang; Zhirui Wang
Journal:  Mol Oncol       Date:  2020-03-13       Impact factor: 6.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.